Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological diseases associated with dysregulated brain cortisol.
Actinogen Medical’s lead compound, Xanamem®, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive decline in Alzheimer’s disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment.
There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms.
Actinogen’s clinical programme to date has demonstrated the safety and tolerability of Xanamem once daily in more than 200 healthy elderly volunteers and patients with Alzheimer’s disease. A statistically significant improvement was observed on computerised cognition testing. These results, along with other data recently generated, confirm 11β-HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment.
The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2021. The XanaMIA study is planned to be conducted in two parts and is designed to study improvements in cognitive ability in older volunteers, and in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease. The XanaFX study studying male patients aged 12 to 18 will assess Xanamem’s effects on cognition, anxiety, sleep and behavioural problems.
Actinogen Medical’s lead compound, Xanamem®, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive decline in Alzheimer’s disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment.
There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms.
Actinogen’s clinical programme to date has demonstrated the safety and tolerability of Xanamem once daily in more than 200 healthy elderly volunteers and patients with Alzheimer’s disease. A statistically significant improvement was observed on computerised cognition testing. These results, along with other data recently generated, confirm 11β-HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment.
The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2021. The XanaMIA study is planned to be conducted in two parts and is designed to study improvements in cognitive ability in older volunteers, and in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease. The XanaFX study studying male patients aged 12 to 18 will assess Xanamem’s effects on cognition, anxiety, sleep and behavioural problems.
Location: Australia, New South Wales, Sydney
Employees: 1-10
Founded date: 2014
Mentions in press and media 7
| Date | Title | Description |
| 29.08.2024 | Actinogen's Xanamem: A Beacon of Hope in Depression Treatment | In the vast landscape of mental health treatments, a new contender is emerging. Actinogen Medical, an Australian biotechnology company, has unveiled promising results from its XanaCIDD Phase 2a trial. This trial investigates Xanamem, a nove... |
| 26.08.2024 | Actinogen announces further positive results on depression in the XanCIDD phase 2a trial | Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression... |
| 26.08.2024 | Actinogen announces further positive results on depression in the XanCIDD phase 2a trial | Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression... |
| 13.10.2023 | Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston | Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychia... |
| 26.09.2023 | Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update | Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitive im... |
| 30.03.2023 | Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference | A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 202... |
| 10.11.2021 | AGM Presentations | For personal use only ASX ANNOUNCEMENT AGM Presentations Sydney, 10 November 2021. Actinogen Medical ASX:ACW ("ACW" or "the Company") is pleased to attach the Chair's Address and CEO's presentation to be presented at tod... |